Skip to main content

Matritech, Bruker Daltonics To Develop Mass Spec For Cancer Diagnostics

NEW YORK, May 20-Bruker Daltonics and Matritech said today that they will work together to develop an automated mass spectrometer for proteomics-based clinical cancer diagnostics.


The two companies will partner to adapt Bruker's MALDI-TOF spectrometer technology to perform tests for the early detection of prostate and breast cancer.


The resulting system will be "turn-key," said Matritech COO and president David Corbet in a statement, allowing clinical laboratories to deliver the company's proprietary tests to market quickly.


Financial details were not disclosed.


Matritech, based in Newton, Mass., develops proteomics-based diagnostics for early cancer detection. The company has identified markers associated with breast, bladder, prostate, cervical and colon cancers, and has a bladder cancer test currently on the market. The company is publicly owned.


Bruker Daltonics, based in Billerica, Mass., is a major provider of mass spectrometry and analysis systems.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.